Immunoadjuvant potential of cross-linked dextran microspheres mixed with chitosan nanospheres encapsulated with tetanus toxoid

References

• Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. 2004. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Control Release. 100:5–28.
   PubMed Web of Science ®Google Scholar
• Amin M, Jaafari MR, Tafaghodi M. 2009. Impact of chitosan coating of anionic liposomes on clearance rate, mucosal and systemic immune responses following nasal administration in rabbits. Colloids Surf B Biointerfaces. 74:225–229.
   PubMed Web of Science ®Google Scholar
• Amorij JP, Kersten GF, Saluja V, Tonnis WF, Hinrichs WL, Slutter B, Bal SM, Bouwstra JA, Huckriede A, Jiskoot W. 2012. Towards tailored vaccine delivery: needs, challenges and perspectives. J Control Release. 161:363–376.
   PubMed Web of Science ®Google Scholar
• Arthanari S, Mani G, Peng MM, Jang HT. 2016. Chitosan-HPMC-blended microspheres as a vaccine carrier for the delivery of tetanus toxoid. Artif Cells Nanomed Biotechnol. 44:517–523.
   PubMed Web of Science ®Google Scholar
• Barhate G, Gautam M, Gairola S, Jadhav S, Pokharkar V. 2014. Enhanced mucosal immune responses against tetanus toxoid using novel delivery system comprised of chitosan-functionalized gold nanoparticles and botanical adjuvant: characterization, immunogenicity, and stability assessment. J Pharm Sci. 103:3448–3456.
   PubMed Web of Science ®Google Scholar
• Chandler SG, Ilium L, Thomas NW. 1991. Nasal absorption in rats. II. Effect of enhancers on insulin absorption and nasal histology. Int J Pharm. 76:61–70.
   Web of Science ®Google Scholar
• Dehghan S, Tafaghodi M, Bolourieh T, Mazaheri V, Torabi A, Abnous K, Tavassoti Kheiri M. 2014. Rabbit nasal immunization against influenza by dry-powder form of chitosan nanospheres encapsulated with influenza whole virus and adjuvants. Int J Pharm. 475:1–8.
   PubMed Web of Science ®Google Scholar
• Dehghan S, Tavassoti Kheiri M, Tabatabaiean M, Darzi S, Tafaghodi M. 2013. Dry-powder form of chitosan nanospheres containing influenza virus and adjuvants for nasal immunization. Arch Pharm Res. 36:981–992.
   PubMed Web of Science ®Google Scholar
• Eldridge JH, Staas JK, Meulbroek JA, Tice TR, Gilley RM. 1991. Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect Immun. 59:2978–2986.
   PubMed Web of Science ®Google Scholar
• Elsabee MZ, Morsi RE, Al-Sabagh AM. 2009. Surface active properties of chitosan and its derivatives. Colloids Surf B Biointerfaces. 74:1–16.
   PubMed Web of Science ®Google Scholar
• Garmise RJ, Staats HF, Hickey AJ. 2007. Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination. AAPS Pharm Sci Tech. 8:E81.
   PubMed Web of Science ®Google Scholar
• Gavini E, Hegge AB, Rassu G, Sanna V, Testa C, Pirisino G, Karlsen J, Giunchedi P. 2006. Nasal administration of carbamazepine using chitosan microspheres: in vitro/in vivo studies. Int J Pharm. 307:9–15.
   PubMed Web of Science ®Google Scholar
• Ghendon Y, Markushin S, Krivtsov G, Akopova I. 2008. Chitosan as an adjuvant for parenterally administered inactivated influenza vaccines. Arch Virol. 153:831–837.
   PubMed Web of Science ®Google Scholar
• Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher AN, Davis SS. 2001. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev. 51:81–96.
   PubMed Web of Science ®Google Scholar
• Illum L, Jørgensen H, Bisgaard H, Krogsgaard O, Rossing N. 1987. Bioadhesive microspheres as a potential nasal drug delivery system. Int J Pharm. 39:189–199.
   Web of Science ®Google Scholar
• Jubeh TT, Barenholz Y, Rubinstein A. 2004. Differential adhesion of normal and inflamed rat colonic mucosa by charged liposomes. Pharm Res. 21:447–453.
   PubMed Web of Science ®Google Scholar
• Khameneh B, Momen-nejad M, Tafaghodi M. 2014. In vivo evaluation of mucoadhesive properties of nanoliposomal formulations upon coating with trimethylchitosan polymer. Nanomed J. 1:147–154.
   Google Scholar
• Khodaverdi E, Heidari Z, Tabassi SA, Tafaghodi M, Alibolandi M, Tekie FS, Khameneh B, Hadizadeh F. 2015 . Injectable supramolecular hydrogel from insulin-loaded triblock PCL-PEG-PCL copolymer and γ-cyclodextrin with sustained-release property. AAPS PharmSciTech. 16:140–149.
   PubMed Web of Science ®Google Scholar
• Mohaghegh M, Tafaghodi M. 2011. Dextran microspheres could enhance immune responses against PLGA nanospheres encapsulated with tetanus toxoid and Quillaja saponins after nasal immunization in rabbit. Pharm Dev Technol. 16:36–43.
   PubMed Web of Science ®Google Scholar
• Mohajer M, Khameneh B, Tafaghodi M. 2014. Preparation and characterization of PLGA nanospheres loaded with inactivated influenza virus, CpG-ODN and Quillaja saponin. Iran J Basic Med Sci. 17:722–726.
   PubMed Web of Science ®Google Scholar
• Nakamura F, Ohta R, Machida Y, Nagai T. 1996. In vitro and in vivo nasal mucoadhesion of some water-soluble polymers. Int J Pharm. 134:173–181.
   Web of Science ®Google Scholar
• Pereswetoff-Morath L, Edman P. 1995. Dextran microspheres as a potential nasal drug delivery system for insulin-in vitro and in vivo properties. Int J Pharm. 124:37–44.
   Web of Science ®Google Scholar
• Sadighi A, Ostad SN, Rezayat SM, Foroutan M, Faramarzi MA, Dorkoosh FA. 2012 . Mathematical modelling of the transport of hydroxypropyl-β-cyclodextrin inclusion complexes of ranitidine hydrochloride and furosemide loaded chitosan nanoparticles across a Caco-2 cell monolayer. Int J Pharm. 422:479–488.
   PubMed Web of Science ®Google Scholar
• Sajadi Tabassi SA, Tafaghodi M, Jaafari MR. 2008. Induction of high antitoxin titers against tetanus toxoid in rabbits by intranasal immunization with dextran microspheres. Int J Pharm. 360:12–17.
   PubMed Web of Science ®Google Scholar
• Slane JA, Vivanco JF, Rose WE, Squire MW, Ploeg HL. 2014. The influence of low concentrations of a water soluble poragen on the material properties, antibiotic release, and biofilm inhibition of an acrylic bone cement. Mater Sci Eng C Mater Biol Appl. 42:168–176.
   PubMed Web of Science ®Google Scholar
• Tafaghodi M, Eskandari M. 2012. The mucosal adjuvant potential of cross-linked dextran microspheres as dry powder. Iran J Basic Med Sci. 15:873–879.
   PubMed Web of Science ®Google Scholar
• Tafaghodi M, Rastegar S. 2010. Preparation and in vivo study of dry powder microspheres for nasal immunization. J Drug Target. 18:235–242.
   PubMed Web of Science ®Google Scholar
• Tafaghodi M, Sajadi Tabasi SA, Jaafari MR. 2006a. Formulation, characterization and release studies of alginate microspheres encapsulated with tetanus toxoid. J Biomater Sci Polym Ed. 17:909–924.
   PubMed Web of Science ®Google Scholar
• Tafaghodi M, Sajadi Tabassi S, Jaafari MR. 2010. Nasal immunization by (PLGA) nanospheres encapsulated with tetanus toxoid and (CpG-ODN). Iran J Pharmaceut Res. 6:151–158.
   Google Scholar
• Tafaghodi M, Sajadi Tabassi SA, Jaafari MR. 2006b. Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN. Int J Pharm. 319:37–43.
   PubMed Web of Science ®Google Scholar
• Turker S, Onur E, Ozer Y. 2004. Nasal route and drug delivery systems. Pharm World Sci. 26:137–142.
   PubMed Web of Science ®Google Scholar
• Xu Y, Du Y. 2003. Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles. Int J Pharm. 250:215–226.
   PubMed Web of Science ®Google Scholar
• Yoksan R, Chirachanchai S. 2008. Amphiphilic chitosan nanosphere: studies on formation, toxicity, and guest molecule incorporation. Bioorg Med Chem. 16:2687–2696.
   PubMed Web of Science ®Google Scholar